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ABSTRACT: Multidrug resistance-associated protein 1
(MRP1) is a drug eﬄux transporter that has been implicated
in the pathology of several neurological diseases and is
associated with development of multidrug resistance. To
enable measurement of MRP1 function in the living brain, a
series of 6-halopurines decorated with ﬂuorinated side chains
have been synthesized and evaluated as putative pro-drug
tracers. The tracers were designed to undergo conjugation
with glutathione within the brain and hence form the
corresponding MRP1 substrate tracers in situ. 6-Bromo-7-(2-
[18F]ﬂuoroethyl)purine showed good brain uptake and rapid
metabolic conversion. Dynamic PET imaging demonstrated a
marked diﬀerence in brain clearance rates between wild-type and mrp1 knockout mice, suggesting that the tracer can allow
noninvasive assessment of MRP1 activity in vivo.
■ INTRODUCTION
Drug eﬄux transporters of the ATP-binding cassette (ABC)
family of proteins mediate active transport of molecules across
cell membranes and physiological barriers, and they have a
major impact on the pharmacological behavior of most of the
drugs in use today.1,2 ABC transporters have complementary
substrate scope and expression patterns, and they maintain
chemical homeostasis by extruding toxins and xenobiotics,
including drugs, from cells and tissues.3−6 In particular,
multidrug resistance-associated proteins (MRPs), P-glycopro-
tein (P-gp), and breast cancer-related protein (BCRP) are
believed to play a key role in the development of multidrug
resistance by extruding an array of therapeutic drugs, resulting
in reduced access to their target sites, and hence rendering
them ineﬀective.
MRP1, which is encoded by the ABCC1 gene, is ubiquitously
expressed in the body but is found at elevated levels in the
lungs, testis, kidneys, heart, and placenta, as well as at
physiological barriers including the blood−brain barrier
(BBB) and the blood−cerebrospinal ﬂuid barrier.7−10 In
contrast to P-gp, it is localized on the basolateral membranes
in polarized cells. In the rat brain, MRP1 is present at higher
levels in the astrocytes than in brain capillary endothelial cells.11
MRP1 functions mainly as a cotransporter of amphipathic
organic anions. It can transport a variety of drugs, endogenous
metabolites, xenobiotics, and hydrophobic drugs or other
compounds that are conjugated to the anionic tripeptide
glutathione (GSH), glucuronic acid, or sulfate.2,4,5 Because
MRP1 also transports oxidized GSH, glutathione disulﬁde, it is
believed to play additional roles in maintaining GSH homeo-
stasis and regulating the redox state of cells.8,12 The role of
MRPs in BBB permeability has been demonstrated by
experiments in which inhibitors of MRPs, such as probenecid
or MK-571, were shown to enhance drug penetration into the
brain or to inhibit drug eﬄux from isolated brain endothelial
cells.13
Upregulation of MRP1 is associated with drug resistance in a
variety of solid tumors, including lung, breast, and prostate
cancers,14 and has been shown to correlate with a poor
response to treatment.10,15 Mice lacking intact mrp1 gene have
altered response to inﬂammatory stimuli and show increased
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toxic response to the anticancer drug etoposide.16 Elevated
MRP1 expression is also associated with refractory epilepsy,17,18
although the ability of MRP1 to transport antiepileptic drugs
remains unclear.19,20 There is also evidence suggesting that
MRP1 function may be impaired in patients with Alzheimer’s
disease,21 and recent preclinical studies have provided
compelling evidence for a role of this transporter in the
clearance of amyloid-β (Aβ) peptides from the brain.22,23
Noninvasive imaging with positron emission tomography
(PET) can enable assessment of MRP1 function in vivo and
holds considerable potential as a tool to elucidate the role of
MPR1 in human diseases, and to evaluate experimental
treatments aimed at modulating transporter function.
To enable quantiﬁcation of MRP1 function in the brain with
PET, Okamura and co-workers recently applied a novel
imaging concept, referred to as the metabolite extrusion
method (MEM), which relies on a pro-drug/drug approach.24
The method was experimentally demonstrated using 6-bromo-
7-[11C]methylpurine ([11C]7m6BP) as the pro-drug tracer.25
Following administration, [11C]7m6BP readily enters the brain
and is subsequently converted to the corresponding GSH
conjugate, which acts as a substrate for MRP1 (Figure 1). This
enables MPR1 activity to be correlated directly to the eﬄux rate
of radioactivity from the brain because the GSH conjugate S-[6-
(7-[11C]methylpurinyl)]glutathione (PSG) is unable to cross
the BBB by passive diﬀusion. While [11C]7m6BP enables
imaging of MRP1 activity in rodents, the short half-life of
carbon-11 (20.4 min) makes it diﬃcult to determine the
metabolic proﬁle of the tracer in animal models. It also
precludes dynamic imaging over prolonged periods of time and
may be problematic for applications in higher species, such as
primates and humans, which are likely to display lower rates of
enzymatic GSH conjugation.26 To address these limitations, we
have prepared and evaluated a series of ﬂuorine-18 (half-life
110 min) labeled 6-halopurines as putative pro-drug tracers for
dynamic imaging of MRP1 function in the brain.
■ RESULTS AND DISCUSSION
Chemistry. We explored two alternative strategies for
preparation of ﬂuorine-18 labeled 6-halopurines, namely, direct
labeling of derivatives bearing ﬂuoroalkyl chains or indirect
labeling via click chemistry to give the resulting radiolabeled
triazoles. The triazole-functionalized 6-halopurines 7−10 were
synthesized by copper(I)-catalyzed cycloaddition of the
corresponding alkynes (3−6) with 2-ﬂuoroethyl azide as
previously reported (Scheme 1).27 The N-ﬂuoroalkylpurines
11−13 and the corresponding tosylate precursors 14−16 were
prepared by base-promoted N-alkylation of 6-chloropurine (1)
and 6-bromopurine (2) using a modiﬁed literature procedure.28
Alkylation provided the N7-isomers 11−16 in 4−13% yield,
with the corresponding N9-isomers constituting the major
products (40−65% yield). The increased polarity of the N7-
isomers relative to their N9 alkylated counterparts allowed
separation by ﬂash chromatography on silica gel.29,30
Figure 1. (a) Metabolic extrusion method (MEM): the pro-drug tracer crosses the BBB by passive diﬀusion (K1) and within the brain rapidly
undergoes enzymatic conversion (k3) to a hydrophilic radioactive metabolite (tracer). If the passive diﬀusion of the tracer across the BBB is
negligible, the activity of the drug eﬄux pump can be correlated to the clearance rate of the tracer (k4) from the brain. (b) Metabolic conversion of
[11C]7m6BP to the MRP1 substrate S-[6-(7-[11C]methylpurinyl)]glutathione (PSG) by GSTs in the brain.
Scheme 1. Synthesis of Fluorinated 6-Halopurine Derivativesa
aReagents and conditions: (i) alkylating agent (1.3 equiv), NaH (1.1 equiv), DMF, overnight, rt; (ii) 2-ﬂuoroethyl azide (1.3 equiv), CuSO4 (0.05
equiv), sodium ascorbate (0.1 equiv), DMF, 4 h, rt; (iii) K222/K2CO3 (30:15 mM), [
18F]ﬂuoride, 15 min, 80 °C.
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Conjugation of the N7-ﬂuorethyl analogue 11 with GSH under
basic conditions24 provided S-[6-(7-(2-ﬂuoroethyl)purinyl)]-
glutathione (17) in 84% yield as a nonradioactive reference
compound for biological studies.
Radiochemistry. The triazole-functionalized purines [18F]9
and [18F]10 were prepared in 40% and 55% isolated
radiochemical yield (RCY), respectively, by ligand-accelerated
copper(I)-catalyzed cycloaddition of the respective alkyne
precursors 5 and 6 with [18F]ﬂuoroethyl azide as reported
elsewhere.27 Treatment of the tosylate precursors 14−16 with
non-carrier-added (nca) [18F]ﬂuoride in the presence of
Kryptoﬁx 222 (K222) and sodium carbonate provided the
purines [18F]11−[18F]13 in 20−27% analytical RCY. The
labeling reactions also yielded a lipophilic radioactive side
product (up to 10% RCY), most likely due to competing
substitution of the halide in the 6 position with [18F]ﬂuoride.
As expected, the formation of the radioactive side product was
more pronounced for the brominated precursor 15 than for the
6-chloro analogues 14 and 16. The labeled compounds [18F]
11−[18F]13 were obtained in 6−10% decay-corrected isolated
RCY after formulation and sterile ﬁltration, with a synthesis
time of approximately 70 min. The chlorinated analogues [18F]
11 and [18F]13 were isolated with a radiochemical purity of
99% after puriﬁcation using a semipreparative monolithic
HPLC column; however, in the case of 6-bromopurine [18F]12,
this puriﬁcation system gave a broad product peak that partly
overlapped with an unknown radioactive side product. The use
of a particle C18 column improved the separation and enabled
us to obtain [18F]12 with 97% radiochemical purity. When this
puriﬁcation system and low levels of activity (1−1.5 GBq of
[18F]ﬂuoride) were used, the speciﬁc activity (SA) of [18F]12
was in a range of 5−7 GBq/μmol after formulation. Scale up of
the reaction (∼5 GBq of [18F]ﬂuoride) under optimized
conditions improved the SA of [18F]12 to 180 GBq/μmol at
end of synthesis.
Kinetic Studies. The reactivity of the purines 7−13 with
GSH was evaluated by determining the pseudo-ﬁrst-order
nonenzymatic conjugation rates (knon, Table 1). To circumvent
the need for radiolabeled analogues in this assay, we incubated
compounds 7−13 at a concentration of 50 μM with an excess
of GSH (10 mM) in phosphate buﬀer and used HPLC to
analyze the composition of the reaction mixtures over time.
Under these conditions, knon of 7m6BP (0.49 ± 0.001 h
−1) was
comparable to the rate previously reported for [14C]7m6BP
(0.28 ± 0.006 h−1) in the presence of physiological
concentration of GSH (2 mM).26 Purines with bromine in
the 6-position showed 3−4 fold higher conjugation rates than
the corresponding chlorine analogues, with the highest rate
observed for the triazole 8 (0.80 ± 0.02 h−1). The ﬂuoroethyl
derivative 12 was equally reactive to 7m6BP, whereas analogues
of 8 and 11 with extended side chains showed a marked drop in
reactivity.
Biodistribution Studies. Motivated by the ease of
radiolabeling,27 we initially selected the triazole [18F]10 for
biological evaluation in wild-type BALB/c mice. The more
reactive analogue 8 was excluded from biological evaluation
because it was found to gradually hydrolyze in water. However,
[18F]10 showed a negligible brain uptake at 5 min post-
injection, and hence we decided not to further pursue
evaluation of purines bearing triazole side chains. 6-Bromo-7-
(2-ﬂuoroethyl)purine (12), which showed the highest non-
enzymatic GSH conjugation rate of the ﬂuoroalkylated
analogues, gave an initial brain uptake of 3.9% ± 0.5% injected
dose per gram bodyweight (ID/g) at 5 min postinjection (p.i.),
with a gradual clearance of radioactivity from the brain
observed over a period from 15 to 90 min p.i. (Figure 2a).
Intriguingly, the clearance of radioactivity from blood, as well as
most of the other tissues examined (heart, liver, lungs, and
spleen) mirrored that of the brain. A high initial uptake (45%
ID/g at 5 min p.i.) and rapid elimination from the kidneys
pointed to renal clearance as the main route of excretion. The
uptake of radioactivity in bone tissue remained low throughout
the time course of the experiment (∼1% ID/g in femur at 90
min p.i.). The biodistribution of the chlorinated analogue [18F]
11 (Figure 2b) was practically indistinguishable from that of
[18F]12, and while the mean brain uptake at 5 min p.i. was
lower for [18F]11 than for [18F]12, the diﬀerence was not
signiﬁcant (3.5% ± 0.6% ID/g vs 3.9% ± 0.5% ID/g).
Extension of the ﬂuoroalkyl side chain to give [18F]13 did not
alter the initial brain uptake (3.9% ± 0.3% ID/g at 5 min p.i.),
but clearance of radioactivity from the brain was signiﬁcantly
faster than for [18F]11 and [18F]12 (Figure 2c). A gradual
increase of radioactivity levels in bone tissue (4.3% ± 1.6% ID/
g in femur at 60 min p.i.) indicated cleavage of the C−F bond
in vivo. Because compound [18F]12 showed a favorable
biodistribution and the highest nonenzymatic GSH conjugation
rate within the series, it was selected as a lead pro-drug tracer
for further biological evaluation.
Enzymatic Kinetic Studies. The pseudo-ﬁrst-order
enzymatic conjugation rate (kenz) of compound 12 (50 μM)
with GSH (10 mM) was measured in mouse brain
homogenates. HPLC analysis was used to monitor con-
sumption of 12 over time and revealed a clean conversion to
the corresponding GSH conjugate 17 within 15 min (Figure 3).
The rate of enzymatic conjugation (kenz = 39.1 ± 6.1 h
−1 g−1
mL−1) was approximately 2 orders of magnitude higher than
the rate for the nonenzymatic reaction (knon = 0.49 ± 0.001
h−1), demonstrating that 12 is a good substrate for glutathione
S-transferases (GSTs).
Table 1. Nonenzymatic Reaction Rates of 6-Halopurine
Analogues with GSH
aReaction rates of 6-halopurine analogues (50 μM) in phosphate
buﬀer (0.1 M, pH 7.4) in the presence of GSH (10 mM).
Measurements were made in duplicate, and values are represented
as mean ± standard deviation.
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Metabolite Analysis. Radio-HPLC was used to determine
the metabolic proﬁle in plasma and brain tissue after
administration of [18F]12 to wild-type BALB/c. Analysis of
plasma samples showed that [18F]12 was rapidly metabolized,
resulting in formation of the GSH conjugate [18F]17, as well as
additional metabolites. The GSH conjugate [18F]17 repre-
sented 25% ± 3% and 64% ± 5% (n = 3) of the total
radioactivity at 15 and 60 min p.i., respectively, with other
unknown metabolites accounting for the remaining activity
(Figure 4a). In the brain, the metabolic proﬁle remained largely
unchanged over this period of time, with [18F]17 constituting
44% ± 1% (n = 3) and 48% ± 6% (n = 4) of the total
radioactivity at 15 and 60 min p.i., respectively. A similar
metabolic proﬁle was observed in the brain of wild-type FVB
mice (Figure 4b), whereas analysis of brain tissue from mrp1
knockout (KO) FVB mice demonstrated a remarkably clean
conversion of [18F]12 to [18F]17, with no other radioactive
metabolites detected (Figure 4c). Although we have not
determined the structural identity of the metabolites other than
[18F]17, the results are consistent with previous studies of the
Figure 2. Total uptake of radioactivity in selected tissues expressed as % ID/g ± standard deviation (n = 3) after administration of (a) [18F]12, (b)
[18F]11, and (c) [18F]13 in wild-type BALB/c mice over time.
Figure 3. UV chromatograms showing the enzymatic conjugation of
GSH (10 mM) with 6-bromo-7-(2-ﬂuoroethyl)purine 12 (50 μM)
over a period of 2−15 min.
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metabolism of 6-chloropurine, which after GST-mediated
conjugation with GSH undergoes stepwise breakdown
mediated by γ-glutamyltranspeptidase, dipeptidase, and cysteine
conjugate β-lyase to eventually give 6-mercaptopurine.21,31,32
Because this metabolic pathway occurs in the extracellular
space, it relies on MPR1 mediated eﬄux of the glutathione
conjugate from the cytosol,33−35 which could explain why [18F]
17 was the only radioactive metabolite observed in brain tissue
from mrp1 KO FVB mice.
Measurement of the Brain Eﬄux Rates in WT and
mrp1 KO FVB Mice with PET. Dynamic PET was used to
measure the brain radioactivity levels in WT and mrp1 KO FVB
mice after administration of [18F]12. In WT mice, the brain
uptake peaked within 2 min after injection (data not shown),
and in accordance with the biodistribution studies, the
radioactivity levels gradually decreased from 15 min onward.
In mrp1 KO mice, a similar proﬁle was observed at the early
time points; however, in the period from 15 to 60 min, the
radioactivity levels remained largely unchanged in the brain, as
well as in peripheral tissues (Figure 5a,b). The eﬄux rates of
radioactivity from the brain in the period from 15 to 60 min
after administration of [18F]12 were 1.6 ± 0.13 and 0.17 ± 0.02
h−1 in WT and mrp1 KO mice, respectively (Figure 5c). The
results are in excellent agreement with the previously reported
eﬄux rates for [11C]7m6BP (1.4 ± 0.24 and 0.15 ± 0.01 h−1 in
WT and mrp1 KO mice, respectively).25 The marked diﬀerence
in brain eﬄux rates between the two groups of mice strongly
suggests that MRP1 plays a key role in the clearance of the
GSH conjugate [18F]17 from the brain. However, the presence
of multiple radioactive metabolites in the brain after
administration of [18F]12 in WT mice raises questions about
the relative contribution of phase III metabolites to the eﬄux
rate and to what degree the clearance can be aﬀected by
alterations to the enzymatic machinery or expression levels of
other eﬄux pumps. While the brain clearance rate measured
after administration of [18F]12 is likely to reﬂect the eﬄux rate
of drugs that are susceptible to GSH conjugation, further
characterization is required to determine the correlation of the
eﬄux rate to MRP1 activity.
Figure 4. HPLC proﬁle of radioactive metabolites after administration
of [18F]12. (a) Brain and plasma samples 60 min p.i. in WT BALB/c
mice; (b) brain at 15 min (solid line) and 60 min (dotted line) p.i. in
WT FVB mice; (c) brain at 15 min (solid line) and 60 min (dotted
line) p.i. in mrp1 KO FVB mice.
Figure 5. Coronal and sagittal summed images during 32.5−57.5 min after administration of [18F]12 in (a) mrp1 KO FVB mice and (b) WT FVB
mice. (c) Eﬄux rates in WT and in mrp1 KO FVB mice. (d) Brain radioactivity levels expressed as % ID/mL over the period from 15 to 60 min after
injection of [18F]12. The results are expressed as the mean ± standard deviation (n = 4).
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■ CONCLUSION
A series of 6-halopurines decorated with ﬂuorinated side chains
have been synthesized and evaluated as putative pro-drug
tracers for imaging of MRP1 activity in the brain with PET.
Following measurements of the conjugation rates with GSH,
selected derivatives were labeled with ﬂuorine-18, and subjected
to biodistribution and metabolite studies. 6-Halopurines
decorated with ﬂuoroalkyl side chains showed high initial
brain uptake, whereas introduction of triazole containing side
chains proved detrimental for BBB penetration. The lead
compound, 6-bromo-7-(2-[18F]ﬂuoroethyl)purine ([18F]12),
gave a peak brain uptake within 2 min p.i. and was found to
undergo rapid GSH conjugation in vivo, although additional
radioactive metabolites were observed in the brain as well as in
plasma. In biodistribution studies in wild-type mice, a favorable
clearance rate of radioactivity from the brain was observed from
15 to 90 min after administration of [18F]12. Dynamic PET
imaging of wild-type versus mrp1 knockout FVB mice showed a
marked diﬀerence in brain eﬄux rates between the two groups
of mice, suggesting that [18F]12 is a promising pro-drug tracer
for noninvasive measurement of MRP1 activity in the brain.
However, the presence of secondary metabolites in the brain of
wild-type FVB mice raises questions as to their relative
contribution to the clearance rate. Further characterization is
therefore required to determine to what degree the clearance of
radioactivity from the brain following administration of [18F]12
correlates with MRP1 activity.
■ MATERIALS AND METHODS
General. All reagents were purchased from Sigma-Aldrich and used
without further puriﬁcation. NMR spectra were recorded on Bruker
Avance spectrometers operating at a frequency of 500 or 600 MHz for
1H and 125 or 150 MHz for 13C. Chemical shifts (δ) are reported in
ppm downﬁeld from the internal standard tetramethylsilane. High
resolution mass spectra were recorded on a thermo Finnigan
MAT900xp (CI/EI) or a Waters LCT Premier XE (ES) mass
spectrometers. Melting points were determined using a Gallenkamp
Sanyo melting point apparatus. No-carrier-added aqueous [18F]¯uoride
was provided by St Thomas’ Hospital, King’s College London, U.K.
HPLC analyses were performed with an Agilent 1200 series system
equipped with a diode array UV detector (results described are for UV
at λ = 265 nm), and a Raytest GABI star NaI detector. Automated
synthesis was carried out on a HBIII module (Scintomics, Germany).
Isolated radiochemical yields (RCY) were measured using a
Curiementor 4 ion chamber (PTW, Germany). IR spectra were
obtained using a PerkinElmer Spectrum 100 FT-IR spectrometer. All
animal experiments conducted at UCL (London, U.K.) were in
compliance with the United Kingdom Home Oﬃce Animal
Procedures Act of 1986 with approval of the University College
London Animal Ethics Committee. Female BALB/c WT mice were
purchased from Charles River, U.K. All animal experiments conducted
at the Molecular Imaging Center (Chiba, Japan) were in compliance
with the “Recommendations for Handling of Laboratory Animals for
Biomedical Research” compiled by the Committee on Safety and
Ethical Handling Regulations for Laboratory Animal Experiments at
the National Institute of Radiological Sciences. Male FVB WT mice
and mrp1 KO mice were purchased from Taconic Farms, Inc.
(Hudson, NY). Mice weighing 27−33 g (aged 17−22 wk) were used
throughout this study and were allowed free access to food and water.
The nonradioactive reference compounds (7m6BP, 7−13) were
obtained with a purity >95% as determined by analytical HPLC (λ =
265 nm). The radioactive tracers ([18F]10−[18F]13) were obtained
with radiochemical purity ≥97% as determined by analytical radio-
HPLC.
General Procedure for Preparation of the Alkylated 6-
Halopurines. To a solution of 6-halopurine (1 equiv) and NaH (60%
dispersed in oil, 1.1 equiv) in anhydrous DMF was added the
alkylating agent (1.3 equiv) under inert atmosphere. After 24 h at
room temperature, the reaction mixture was diluted with dichloro-
methane (DCM) and washed three times with water. The organic
layer was dried with MgSO4, and the solvent was removed in vacuo.
The residue was puriﬁed by ﬂash chromatography (silica gel as solid
phase) using a gradient of DCM and ethyl acetate (from 0% to 60%
ethyl acetate) to give the N7- and the N9-alkynyl analogues.
6-Chloro-7-(2-ﬂuoroethyl)purine (11). A mixture of 6-chloropurine
(1) (500 mg, 3.23 mmol), (2-ﬂuoroethyl)tosylate (910 mg, 4.21
mmol), and NaH (60% dispersed in oil, 142 mg, 3.56 mmol) in
anhydrous DMF (15 mL) was reacted according to the general
alkylation procedure to give 11 (43 mg, 7%) and the corresponding
N9-isomer 11a (246 mg, 38%) as white solids. Compound 11. 1H
NMR (CDCl3, 500 MHz): δ 8.86 (s, 1 H, H-2), 8.30 (s, 1 H, H-8),
4.86 (s, 2 H, CH2cCH2aF), 4.80 (m, 1 H, CH2dCH2F), 4.76 (m, 1 H,
CH2CH2bF).
13C NMR (CDCl3): δ 162.2, 152.7, 149.8, 142.8, 122.2,
82.2, 80.9, 47.6, 47.4. Accurate mass (EI) m/z calcd for C7H6ClFN4
(M)+ 200.02595, found 200.02670. IR (cm−1): υmax 3096, 3068, 2924,
1845, 1692. Mp: 110 ± 2 °C. Compound 11a. 1H NMR (CDCl3, 500
MHz): δ 8.69 (s, 1 H, H-2), 8.18 (s, 1 H, H-8), 4.77 (dt, JH,F = 46.78
Hz, J1,2 = 4.62 Hz, 2 H, CH2F), 4.59 (t, JH,F = 27.16 Hz, J1,2 = 4.48 Hz,
2 H, CH2CH2F).
13C NMR (CDCl3): δ 152.1, 151.7, 151.2, 145.6,
131.5, 81.7, 80.3, 44.7, 44.5. Accurate mass (EI) m/z calcd for
C7H6ClFN4 (M)
+ 200.02595, found 200.02541. IR (cm−1): υmax 3097,
3076, 2992, 2969, 1876, 1811. Mp: 90 ± 1 °C.
6-Bromo-7-(2-ﬂuoroethyl)purine (12). A mixture of 6-bromopur-
ine (2) (500 mg, 2.51 mmol), (2-ﬂuoroethyl)tosylate (780 mg, 3.27
mmol), and NaH (60% dispersed in oil, 111 mg, 2.76 mmol) in
anhydrous DMF (15 mL) was reacted according to the general
alkylation procedure to give 12 (39 mg, 6%) and the corresponding
N9-isomer 12a (266 mg, 43%) as white solids. Compound 12. 1H
NMR (CDCl3, 600 MHz): δ 8.86 (s, 1 H, H-2), 8.31 (s, 1 H, H-8), 4.9
(bs, 2 H, CH2cCH2aF), 4.85 (t, J1,2 = 4.32 Hz, 1 H, CH2dCH2F), 4.80
(t, J1,2 = 4.20 Hz, 1 H, CH2CH2bF).
13C NMR (CDCl3): δ 161.4,
152.7, 150.1, 133.0, 124.4, 82.1, 80.0, 47.2, 47.1. Accurate mass (CI)
m/z calcd for C7H7BrFN4 (M + H)
+ 245.98381, found 245.98282. IR
(cm−1): υmax 3087, 3051, 2973, 2913, 1873. Mp: 123 ± 2 °C.
Compound 12a. 1H NMR (CDCl3, 600 MHz): δ 8.70 (s, 1 H, H-2),
8.22 (s, 1 H, H-8), 4.80 (dt, JH,F = 46.8 Hz, J1,2 = 4.44 Hz, 2 H, CH2F),
4.60 (dt, JH,F = 27.1 Hz, J1,2 = 4.40 Hz, 2 H, CH2CH2F).
13C NMR
(CDCl3): δ 152.1, 150.4, 145.5, 143.4, 134.2, 81.7, 80.3, 44.7, 44.5.
Accurate mass (CI) m/z calcd for C7H7BrFN4 (M + H)
+ 245.98381,
found 245.98291. IR (cm−1): υmax 3127, 3089, 3065, 2976, 2957, 1851,
1776. Mp: 99 ± 1 °C.
6-Chloro-7-(5-ﬂuoropentyl)purine (13). A mixture of 6-chloropur-
ine (1) (450 mg, 2.91 mmol), (5-ﬂuoropentyl)tosylate (1.3 g, 3.78
mmol), and NaH (60% dispersed in oil, 128 mg, 3.2 mmol) in
anhydrous DMF (15 mL) was reacted according to the general
alkylation procedure to give 13 (90 mg, 13%, white solid) and the
corresponding N9-isomer 13a (327 mg, 46%, colorless oil).
Compound 13. 1H NMR (CDCl3, 600 MHz): δ 8.88 (s, 1 H, H-2),
8.22 (s, 1 H, H-8), 4.49 (t, J = 7.32 Hz, 2 H, CH2(CH2)4F), 4.45 (dt,
JF,H = 47.29 Hz, J1,2 = 5.76 Hz, 2 H, CH2F), 1.99 (m, 2 H,
CH2(CH2)3F), 1.80−1.71 (m, 2 H, CH2CH2F), 1.52 (m, 2 H,
CH2(CH2)2F).
13C NMR (CDCl3): δ 162.2, 152.6, 149.0, 143.1,
122.4, 84.1, 83.0, 47.5, 31.5, 29.9, 29.8, 22.6. Accurate mass (EI) m/z
calcd for C10H12ClFN4 (M)
+ 242.07345, found 242.07359. IR (cm−1):
υmax 3105, 3076, 2932, 2865, 1909, 1811. Mp: 97 ± 1 °C. Compound
13a. 1H NMR (CDCl3, 600 MHz): δ 8.73 (s, 1 H, H-2), 8.12 (s, 1 H,
H-8), 4.42 (dt, JF,H = 47.29 Hz, J1,2 = 5.82 Hz, 2 H, CH2F),4.31 (t, J =
5.82 Hz 2 H, CH2(CH2)4F), 1.98 (m, 2 H, CH2(CH2)3F), 1.78−1.69
(m, 2 H, CH2CH2F), 1.47 (m, 2 H, CH2(CH2)2F).
13C NMR
(CDCl3): δ 152.0, 151.9, 151.9, 415.2, 131.7, 84.2, 83.1, 44.5, 29.8,
29.7, 29.5, 22.5. Accurate mass (EI) m/z calcd for C10H12ClFN4 (M)
+
242.07345, found 242.07342. IR (cm−1): υmax 3074, 2943, 2867.
Analytical HPLC: Luna C18(2) column (3 μm, 50 mm × 4.6 mm,
Phenomenex) using water and methanol containing 0.1% of formic
acid as eluents (methanol content from 15% to 50% over 20 min, ﬂow
1 mL/min, λ = 265 nm). Retention time: 12.9 min.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm401764a | J. Med. Chem. 2014, 57, 1023−10321028
6-Chloro-7-(2-tosyloxyethyl)purine (14). A mixture of 6-chlor-
opurine (1) (500 mg, 3.24 mmol), ethylene di(p-toluenesulfonate)
(1.6 g, 4.21 mmol), and NaH (60% dispersed in oil, 142 mg, 3.56
mmol) in anhydrous DMF (15 mL) was reacted according to the
general alkylation procedure to give 14 (109 mg, 19%) and the
corresponding N9-isomer 14a (466 mg, 41%) as white solids.
Compound 14. 1H NMR (CDCl3, 600 MHz): δ 8.83 (s, 1 H, H-2),
8.19 (s, 1 H, H-8), 7.46 (d, J = 7.8 Hz, 2 H, ArH), 7.07 (d, J = 8.4 Hz,
2 H, ArH), 4.69 (t, J = 4.8 Hz, 2 H, CH2CH2OTs), 4.45 (t, J = 4.8 Hz,
2 H, CH2OTs), 2.33 (s, 3 H, CH3).
13C NMR (CDCl3): δ 162.2,
152.5, 149.9, 145.6, 142.3, 131.1, 130.0, 127.5, 121.6, 67.3, 46.2, 29.8,
21.7. Accurate mass (EI) m/z calcd for C14H13N4O3SCl (M)
+
352.03914, found 352.03958. IR (cm−1): υmax 3110, 3082, 3016,
2970, 1831, 1718. Mp: 166 ± 1 °C. Compound 14a. 1H NMR
(CDCl3, 600 MHz): δ 8.56 (s, 1 H, H-2), 8.06 (s, 1 H, H-8), 7.45 (d, J
= 8.4 Hz, 2 H, ArH), 7.09 (d, J = 7.8 Hz, 2 H, ArH), 4.51 (t, J = 4.8
Hz, 2 H, CH2CH2OTs), 4.45 (t, J = 4.8 Hz, 2 H, CH2OTs), 2.37 (s, 3
H, CH3).
13C NMR (CDCl3): δ 152.2, 151.15, 151.12, 145.6, 145.59,
131.6, 131.4, 129.8, 127.6, 66.2, 43.7, 21.7. Accurate mass (EI) m/z
calcd for C14H13N4O3SBr (M)
+ 352.03914, found 352.03974. IR
(cm−1): υmax 3112, 3083, 2960, 1765. Mp: 175 ± 1 °C.
6-Bromo-7-(2-tosyloxyethyl)purine (15). A mixture of 6-bromo-
purine (2) (500 mg, 2.51 mmol), ethylene di(p-toluenesulfonate) (1.2
g, 3.27 mmol), and NaH (60% dispersed in oil, 111 mg, 2.76 mmol) in
anhydrous DMF (15 mL) was reacted according to the general
alkylation procedure to give 15 (40 mg, 4%) and the corresponding
N9-isomer 15a (399 mg, 40%) as white solids. Compound 15. 1H
NMR (CDCl3, 600 MHz): δ 8.78 (s, 1 H, H-2), 8.19 (s, 1 H, H-8),
7.46 (d, J = 8.22 Hz, 2 H, ArH), 7.07 (d, J = 8.10 Hz, 2 H, ArH), 4.72
(t, J = 4.86 Hz, 2 H, CH2CH2OTs), 4.48 (t, J = 5.04 Hz, 2 H,
CH2OTs), 2.33 (s, 3 H, CH3).
13C NMR (CDCl3): δ 161.3, 152.4,
150.1, 145.6, 1325.5, 131.1, 129.9, 127.5, 123.8, 67.3, 45.7, 21.7.
Accurate mass (CI) m/z calcd for C14H14N4O3SBr (M + H)
+
396.99700, found 396.99825. IR (cm−1): υmax 2996, 2965, 2920,
1917, 1772. Mp: 165 ± 1 °C. Compound 15a. 1H NMR (CDCl3, 600
MHz): δ 8.53 (s, 1 H, H-2), 8.07 (s, 1 H, H-8), 7.45 (d, J = 8.28 Hz, 2
H, ArH), 7.09 (d, J = 7.98 Hz, 2 H, ArH), 4.50 (t, J = 4.44 Hz, 2 H,
CH2CH2OTs), 4.45 (t, J = 4.98 Hz, 2 H, CH2OTs), 2.37 (s, 3 H,
CH3).
13C NMR (CDCl3): δ 151.8, 149.8, 145.6, 145.5, 143.3, 134.2,
131.3, 129.8, 127.5, 66.2, 43.7, 21.7. Accurate mass (CI) m/z calcd for
C14H14N4O3SBr (M + H)
+ 396.99700, found 396.99792. IR (cm−1):
υmax 3113, 2989, 2959, 2914, 1921. Mp: 175 ± 1 °C.
6-Chloro-7-(5-tosyloxypentyl)purine (16). A mixture of 6-chlor-
opurine (1) (500 mg, 3.24 mmol), pentane di(p-toluenesulfonate)
(1.7 g, 4.21 mmol), and NaH (60% dispersed in oil, 142 mg, 3.56
mmol) in anhydrous DMF (15 mL) was reacted according to the
general alkylation procedure to give 16 (115 mg, 9%) and the
corresponding N9-isomer 16a (810 mg, 64%) as yellow oils.
Compound 16. 1H NMR (CDCl3, 600 MHz): δ 8.86 (s, 1 H, H-2),
8.22 (s, 1 H, H-8), 7.74 (d, J = 7.80 Hz, 2 H, ArH), 7.33 (d, J = 7.80
Hz, 2 H, ArH), 4.44 (t, J = 7.20 Hz, 2 H, CH2(CH2)4OTs), 4.00 (t, J =
6.0 Hz, 2 H, CH2OTs), 2.43 (s, 3 H, CH3), 1.91 (m, 2 H,
CH2(CH2)3OTs), 1.71 (m, 2 H, CH2CH2OTs), 1.41 (m, 2 H,
CH2(CH2)2OTs).
13C NMR (CDCl3): δ 162.1, 152.6, 149.1, 145.1,
143.0, 132.9, 130.1, 127.9, 122.4, 69.8, 47.3, 44.5, 31.2, 29.6, 22.6, 21.8.
Accurate mass (ES+) m/z calcd for C17H20ClN4O3S (M + H)
+
395.0945, found 395.0944. IR (cm−1): υmax 3059, 2937, 2865.
Analytical HPLC: Chromolith performance column, RP18-e (100
mm × 4.6 mm, Merck), using water and methanol containing 0.1% of
formic acid as eluents (methanol content from 15% to 70% over 9
min, ﬂow 3 mL/min, λ = 265 nm). Retention time: 6.8 min.
Compound 16a. 1H NMR (CDCl3, 600 MHz): δ 8.73 (s, 1 H, H-2),
8.06 (s, 1 H, H-8), 7.40 (d, J = 7.80 Hz, 2 H, ArH), 7.32 (d, J = 8.40
Hz, 2 H, ArH), 4.27 (t, J = 7.20 Hz, 2 H, CH2(CH2)4OTs), 4.00 (m, 2
H, CH2OTs), 2.43 (s, 3 H, CH3), 1.91 (m, 2 H, CH2(CH2)3OTs),
1.70 (m, 2 H, CH2CH2OTs), 1.39 (m, 2 H, CH2(CH2)2OTs).
13C
NMR (CDCl3): δ 152.0, 151.9, 151.2, 145.2, 145.0, 132.9, 131.7,
130.0, 127.9, 69.9, 44.3, 29.4, 29.3, 22.8, 21.8. Accurate mass (ES+) m/
z calcd for C17H20ClN4O3S (M + H)
+ 395.0945, found 395.0941. IR
(cm−1): υmax 3070, 2942, 2867, 1737. Analytical HPLC: Luna C18(2)
column (3 μm, 50 mm × 4.6 mm, Phenomenex) using water and
methanol containing 0.1% of formic acid as eluents (methanol content
from 25% to 65% over 20 min, ﬂow 1 mL/min, λ = 265 nm).
Retention time: 15.6 min.
5-Tosyloxy-1-pentanol. 1,5-Pentanediol (4.0 g, 40 mmol), p-
toluenesulfonyl chloride (7.3 g, 42 mmol), and pyridine (3.9 mL, 50
mmol) were dissolved in DCM (20 mL), and the resulting solution
was stirred overnight at room temperature. The reaction mixture was
diluted with DCM and washed three times with water. The organic
layer was dried with MgSO4, and the solvent was removed in vacuo.
The crude mixture was suspended in methanol to precipitate pentane
di(p-toluenesulfonate). The white solid was removed by ﬁltration, and
the ﬁltrate was concentrated in vacuo. The resulting crude product was
puriﬁed by liquid chromatography on silica gel using a gradient of
petroleum ether and ethyl acetate (from 0% to 60% of ethyl acetate).
5-Tosyloxy-1-pentanol: 53% yield (3.8 g). 1H NMR (CDCl3, 600
MHz): δ 7.78 (d, J = 8.40 Hz, 2 H, ArH), 7.34 (d, J = 7.80 Hz, 2 H,
ArH), 4.02 (t, J = 6.60 Hz, 2 H, CH2OH), 4.59 (t, J = 6.60 Hz, 2 H,
CH2OTs), 2.44 (s, 3 H, CH3), 1.68−1.53 (m, 2 H, CH2CH2OH),
1.52−1.49 (m, 2 H, CH2CH2OTs), 1.41−1.36 (m, 2 H,
CH2CH2CH2OH).
13C NMR (CDCl3): δ 144.9, 133.1, 129.8, 128.0,
70.6, 62.6, 60.6, 53.6, 31.9, 28.7, 21.6. Accurate mass (EI) m/z calcd
for C12H18O4S (M
+) 258.09203, found 258.09246. Pentane di(p-
toluenesulfonate): 18% yield (2.8 g). 1H NMR (CDCl3, 600 MHz): δ
7.76 (d, J = 8.40 Hz, 4 H, ArH), 7.34 (d, J = 7.80 Hz, 4 H, ArH), 3.96
(t, J = 6.00 Hz, 4 H, CH2OTs), 2.45 (s, 6 H, CH3), 1.60 (m, 4 H,
TsOCH2CH2), 1.34 (m, 2 H, TsOCH2CH2CH2).
13C NMR (CDCl3):
δ 145.0, 133.0, 129.8, 128.2, 70.1, 28.3, 21.6, 21.5. Accurate mass (CI)
m/z calcd for C19H25O6S2 (M + H)
+ 413.10925, found 413.10940.
(5-Fluoropentyl)tosylate. 5-Tosyloxy-1-pentanol (1 g, 3.87
mmol) and diethylaminosulfur triﬂuoride (DAST) (2.6 mL, 19.4
mmol) were dissolved in DCM (20 mL) at 0 °C, and the resulting
solution was allowed to gradually reach room temperature with stirring
over 4 h. The reaction mixture was diluted with DCM (100 mL) and
washed with brine (100 mL × 1) and twice with water (100 mL × 2).
The organic layer was dried with MgSO4, and the solvent was removed
in vacuo. The product was puriﬁed by liquid chromatography on silica
gel using petrol ether and ethyl acetate (90:10), to give the title
compound as colorless oil in 70% yield (700 mg). 1H NMR (CDCl3,
600 MHz): δ 7.78 (d, J = 8.28 Hz, 2 H, ArH), 7.34 (d, J = 8.11 Hz, 2
H, ArH), 4.39 (dt, JF,H = 47.23 Hz, J1,2 = 6.00 Hz, 2 H, CH2F), 4.03 (t,
J = 6.36 Hz, 2 H, TsOCH2), 2.44 (s, 3 H, CH3), 1.71−1.65 (m, 2 H,
TsOCH2CH2), 1.64−1.59 (m, 2 H, FCH2CH2), (m, 2 H,
FCH2CH2CH2).
13C NMR (CDCl3): δ 144.9, 133.1, 130.0, 127.8,
84.3, 83.2, 70.4, 29.9, 29.7, 28.6, 27.8, 21.5, 21.4. Accurate mass (EI)
m/z calcd for C12H17FO3S (M)
+ 260.08769, found 260.08743.
S-[6-(7-(2-Fluoroethyl)purinyl)]glutathione (17). Compound
17 was prepared following a modiﬁed literature procedure.24 Brieﬂy,
11 (10 mg, 0.05 mmol) and GSH (33.7 mg, 0.11 mmol) dissolved in
300 μL of a solution of NaOH (1 M) and ethanol (1:1) were stirred
for 4 h at 50 °C. The crude mixture was ﬁltered over a plug of silica,
and the silica plug was washed with a solution of ethyl acetate/
methanol (1:1), and the product was eluted with methanol. The
fraction containing the product was concentrated under reduced
pressure, and the crude product was further puriﬁed by semi-
preperative HPLC using a Zorbax ODS column (C18, 5 μm, 9.4 mm
× 250 mm, Agilent). The ﬂow rate was 2 mL/min with a mobile phase
of water and methanol containing 0.1% triﬂuoroacetic acid (TFA).
The methanol content was increased from 10% to 30% over 20 min
and then kept constant at 30% for 7 min. The UV absorbance detector
was set at 288 nm. Retention time of 17: 23.4 min. Compound 17 was
isolated in 84% yield (25 mg). 1H NMR (D2O, 500 MHz): δ 8.72 (s, 1
H, H-2), 8.49 (s, 1 H, H-8), 4.83 (s, 2 H, CH2aCH2cF), 4.78 (m, 2 H,
CH-Cys, CH2bCH2F), 4.75 (t, J = 1.86 Hz, 1 H, CH2CH2dF), 3.95 (dd,
J = 14.43 Hz, J = 5.12 Hz, 1 H, CH2a-Cys), 3.93 (s, 2 H, CH2−Gly),
3.81 (t, J = 6.56 Hz, 1 H, CH-Glu), 3.66 (dd, J = 14.46 Hz, J = 8.09
Hz, 1 H, CH2b-Cys), 2.39−2.33 (m, 2 H, CH2α-Glu), 2.01−1.98 (m, 2
H, CH2β-Glu).
13C NMR (D2O): δ 175.0, 173.5, 173.0, 172.6, 156.7,
154.9, 152.1, 150.1, 124.0, 83.6, 82.5, 53.7, 53.5, 48.9, 48.7, 41.8, 31.7,
31.2, 26.3. Accurate mass (ES−) m/z calcd for C17H21FN7O6S (M −
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H)− 470.1258, found 470.1243. IR (cm−1): υmax 3286, 2932, 2595.
Mp: 191 ± 2 °C.
General Procedure for the Radiosynthesis of [18F]11−13.
[18F]ﬂuoride in water (∼1−5 GBq) was trapped on a QMA cartridge
(Waters Sep-Pak light) and released with 0.5 mL of Kryptoﬁx 222 and
potassium carbonate mixture (30:15 mM) dissolved in acetonitrile/
water (85:15). The solvent was removed by heating at 90 °C under a
stream of nitrogen. Acetonitrile (0.5 mL) was added, and the
distillation was continued. This procedure was repeated twice. The
dried mixture was cooled to room temperature by a stream of
nitrogen, and a solution of precursor (14−16, 7 μmol in 0.4 mL
anhydrous acetonitrile) was added. The resulting mixture was stirred at
80 °C for 15 min. The solvent volume was reduced to 0.2 mL under a
stream of nitrogen, then diluted with 2 mL water and passed through a
C18 cartridge (Waters Sep-Pak light). After elution, the fraction
containing the radioactive product was subsequently puriﬁed by
semipreparative HPLC. C18 cartridge formulation: the fraction
containing the radioactive product ([18F]11−[18F]13) was diluted
with water to reduce the organic content to 5−10% depending on the
lipophilicity of the radiolabeled product and loaded onto a C18
cartridge. The cartridge was washed with 2 mL of water, and the
product was then released with 1 mL of pure ethanol. The volume
fraction was reduced to ∼100 μL and diluted with saline to give an
ethanol concentration of 5% before sterile ﬁltration.
6-Chloro-7-(2-[18F]ﬂuoroethyl)purine ([18F]11). Hands-on reaction:
analytical RCY, 27% ± 6% (n = 3). Automated synthesis: isolated
RCY, 10% ± 2% (n = 7). [18F]11 was obtained with a radiochemical
purity of 99% and SA of 6 GBq/μmol after sterile ﬁltration.
Precartridge puriﬁcation with a C18 cartridge (Waters Sep-Pak
light): the product [18F]11 was released with 1 mL of 20% ethanol
in water, and the resulting fraction was further diluted with 1 mL of
water. HPLC puriﬁcation was performed on a Chromolith perform-
ance column, RP18-e (100 mm × 10 mm, Merck) using water and
methanol containing 0.1% of formic acid as mobile phase (water/
methanol 95:5 v/v, ﬂow rate 5 mL/min, λ = 254 nm). Retention time:
10 min.
Radiochemical purity and SA of [18F]11 were determined by
analytical HPLC, using a Chromolith performance column, RP18-e
(100 mm × 4.6 mm, Merck), and water and methanol containing 0.1%
of formic acid as mobile phase (methanol content from 5% to 20%
over 5 min, at 20% for 2 min, and up to 70% over 2 min, ﬂow 3 mL/
min, λ = 265 nm). Retention time: 4.0 min.
6-Bromo-7-(2-[18F]ﬂuoroethyl)purine ([18F]12). Hands-on reaction:
analytical RCY, 17.2% ± 1.8% (n = 3). Automated synthesis: isolated
RCY, 11% ± 3% (n = 7). [18F]12 was obtained with a radiochemical
purity of 97% and SA of 180 GBq/μmol at end of synthesis.
Precartridge puriﬁcation with a C18 cartridge (Waters Sep-Pak
classical): the product [18F]12 was released with 1 mL of 30%
ethanol in water, and the resulting fraction was further diluted with 1
mL of water. HPLC puriﬁcation was performed on a Zorbax ODS
(C18, 5 μm, 250 mm × 9.4 mm, Agilent) at room temperature, using
water and methanol containing 0.1% of formic acid as mobile phase
(15% methanol for the ﬁrst 5 min, and from 15% to 30% in 25 min,
ﬂow rate of 3 mL/min, λ = 254 nm). Retention time: 22.5 min.
Radiochemical purity and SA of [18F]12 were determined by
analytical HPLC, using a Luna C18(2) column (3 μm, 50 mm × 4.6
mm, Phenomenex) and water and methanol containing 0.1% formic
acid as mobile phase (methanol content 5% for the ﬁrst 5 min, and
from 5% to 50% over 25 min, ﬂow 1 mL/min, λ = 265 nm). Retention
time: 12.6 min.
6-Chloro-7-(5-[18F]ﬂuoropentyl)purine ([18F]13). Hands-on reac-
tion: analytical RCY 19% ± 6% (n = 3). Automated synthesis: isolated
RCY, 6% ± 1.5% (n = 3). [18F]13 was obtained with a radiochemical
purity of 99% and SA of 2 GBq/μmol after sterile ﬁltration.
Precartridge puriﬁcation with a C18 cartridge (Waters Sep-Pak
light): the product [18F]13 was then released with 0.7 mL of pure
ethanol, and the resulting fraction was further diluted with 1.3 mL of
water. HPLC puriﬁcation was performed on a Chromolith perform-
ance column, RP18-e (100 mm × 10 mm, Merck), using water and
methanol containing 0.1% of formic acid as mobile phase (water/
methanol 70:30 v/v, ﬂow rate 5 mL/min, λ = 254 nm). Retention
time: 7.1 min.
Radiochemical purity and SA of [18F]13 were determined by
analytical HPLC, using a Chromolith performance column, RP18-e
(100 mm × 4.6 mm, Merck), and water and methanol containing 0.1%
of formic acid as mobile phase (methanol content from 20% to 36%
over 6 min, and up to 60% over 3 min, ﬂow 3 mL/min, λ = 265 nm).
Retention time: 5.2 min.
Rate of GSH Conjugation under Nonenzymatic Conditions.
Solutions of GSH (10 mM in 0.1 M phosphate buﬀer, pH = 7.4, 1 mL)
were preincubated at 37 °C for 15 min. The reaction was initiated by
adding a standard solution of 6-halopurine analogue (7−13 and
7m6BP, ∼1 mM in 0.1 M phosphate buﬀer, pH = 7.4) to each tube to
achieve 50 μM as the ﬁnal concentration. At designated intervals (from
5 min to 1−5 h depending on the reactivity of the purine analogues),
aliquots from the resulting reaction mixtures were analyzed by HPLC,
using a Chromolith performance column, RP18-e (100 mm × 4.6 mm,
Merck), and water and methanol containing 0.1% triﬂuoroacetic acid
(TFA) as mobile phase. The ﬂow rate was 3 mL/min, and the UV
absorbance detector was set at 265 nm. The pseudo-ﬁrst-order rate
constants were calculated by plotting the log of the concentration
(mg/L) of the parent 6-halopurine against the time (min).
Measurements were performed in duplicate. The results are expressed
as the mean (h−1) ± standard deviation.
Kinetic Studies of GSH Conjugation in Brain Homogenates.
Wild-type BALB/c mice were decapitated, and the brain was quickly
removed and homogenized in 1 mL of cold phosphate buﬀer (0.1 M,
pH 7.4). A solution of GSH (10 mM in 0.1 M phosphate buﬀer, pH =
7.4, 1 mL) was added. Aliquots of the resulting mixture (1 mL each)
were preincubated at 37 °C for 15 min. The enzymatic GSH
conjugation reaction was initiated by addition of a standard solution of
12 to each tube (∼1 mM in 0.1 M phosphate buﬀer, pH = 7.4) to
achieve 50 μM as the ﬁnal concentration. At predetermined intervals
(0−15 min), the enzymatic reaction was stopped by addition of TFA
(50 μL), and the resulting mixture was centrifuged (5 min, 13000
rpm). The supernatant was collected and analyzed by HPLC
(Chromolith performance column, RP18-e, 100 mm × 4.6 mm,
Merck), using water and methanol containing 0.1% TFA as mobile
phase. The ﬂow rate was 3 mL/min, and the UV absorbance detector
was set at 265 nm. The pseudo-ﬁrst-order constant was calculated by
plotting the log of the concentration (mg/L) of 12 against time (min)
and adjusting for brain homogenate concentration after subtracting
knon. Determinations were made in triplicate. The results are expressed
as the mean (h−1 g−1 mL−1) ± standard deviation.
Biodistribution Studies. Female wild-type BALB/c mice (20 g)
received 1−2 MBq of the radiotracer as an intravenous injection. At
designated intervals (5−90 min p.i.), the mice were anesthetized with
isoﬂurane (5% mixed with medical air at a ﬂow of 2 mL/min) and
sacriﬁced. The organs of interest were removed and weighed, and the
radioactivity was counted with a γ counter. The results were reported
as the mean of percentage injected dose per gram (% ID/g) ±
standard deviation (n = 3).
Plasma Metabolite Analysis in WT Mice. Female wild-type
BALB/c mice (20 g) received 6−8 MBq of the tracer as intravenous
injection. At designated intervals (15 and 60 min p.i.), the mice were
anesthetized with isoﬂurane (5% mixed with medical air at a ﬂow of 2
mL/min), and the blood was collected by cardiac puncture. The blood
was centrifuged for 2 min at 13000 rpm. The plasma was separated,
and the proteins were precipitated with TFA (25% v/v). The sample
was diluted with water (1:1), and the proteins were removed by
centrifugation (2 min at 13000 rpm). The supernatant was collected, a
standard solution containing the reference compounds 12 and 17 (20
μL, 2.5 mM in 0.1 M phosphate buﬀer, pH = 7.4) was added, and the
resulting mixture was analyzed by HPLC (radioactivity detector and
UV detector 265 nm). A Chromolith performance RP18-e (100 mm ×
4.6 mm, Merck) was used as the column, with a mobile phase
consisting of water and methanol with 0.1% TFA (from 2% of
methanol to 5% over 15 min), with a ﬂow rate of 3 mL/min.
Experiments were perfomed in triplicate. The recovery of radioactivity
from the extraction of plasma was >95%.
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Brain Metabolite Analysis in WT and mrp1 KO Mice. Wild-
type and mrp1 KO FVB mice were decapitated 15 and 60 min after
intravenous injection of [18F]12 (15−26 MBq in 0.2−0.3 mL saline;
<0.29 nmol). The head was quickly immersed in liquid nitrogen, and
the brain was removed. The brain was homogenized in 1 mL of cold
phosphate buﬀer (0.1 M, pH 7.4). TFA (50 μL) was added to the
homogenate, which was centrifuged (5 min, 13000 rpm, 4 °C). The
supernatant was collected, diluted 1:1 with H2O, and analyzed by
HPLC consisting of a pump (PU-2089 plus, JASCO, Tokyo, Japan), a
multiwavelength detector (MD-2015 plus, JASCO), a sensitive
positron detector (Ohyo Koken Kogyo Co. Ltd., Tokyo, Japan), and
a Chromolith performance RP-18e (100 mm × 4.6 mm, Merk)
column. The compounds were eluted with a mobile phase of water and
methanol containing 0.1% TFA (from 2% of methanol to 10% over 15
min) at ﬂow rate of 3 mL/min. In this HPLC system, the parent
compound [18F]12 and the GSH conjugate [18F]17 showed a
retention times of 9.5 and 13.2 min, respectively. The recovery of
radioactivity from the extraction from brain was >95%.
Positron Emission Tomography Scanning Procedures. Four
WT mice and four mrp1 KO mice were used for PET scanning with
[18F]12. Body temperature was monitored using a rectal thermometer
throughout PET scanning and was maintained within the normal
range using a heating pad system. Scans were performed with an
Inveon Dedicated PET system (Siemens Medical Solutions, Knoxville,
TN, USA), which has a transaxial ﬁeld of view of 10 cm and an axial
ﬁeld of view of 12.7 cm. The compound [18F]12 (3.6 MBq; <0.04
nmol) was administered as a 0.2 mL intravenous bolus injection to
each mouse, which was maintained under isoﬂurane anesthesia during
the scanning periods. Data were acquired by the animal tomograph for
60 min after injection in 20 frames divided as follows: 4 × 1 min, 8 × 2
min, and 8 × 5 min frames. Without attenuation correction, the data
were reconstructed using Fourier rebinning and ﬁltered back
projection with a Hanning ﬁlter cutoﬀ at the Nyquist frequency into
images with a 128 × 128 matrix size and 3 times zoom, to give a voxel
size of 0.26 × 0.26 × 0.8 mm3. After image reconstruction, volumes of
interest were manually placed on a summed PET image (coronal view
of the brain) and transferred to all of the frames of images to generate
time−radioactivity concentration (Bq/mL) curves for whole brain,
using the ASIPro VM software (CTI Concorde Microsystems,
Knoxville, TN, USA).
Eﬄux Rate Constant in WT and mrp1 KO Mice. Brain
radioactivity expressed as % injected dose per mL (% ID/mL) during
the period of 15 to 60 min after injection of [18F]12 versus time was
ﬁtted to the monoexponential function by linear least-squares
regression to obtain the eﬄux rate constant. The results were
expressed as the mean (h−1) ± standard deviation (n = 4).
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transport of common antiepileptic drugs by human multidrug
resistance-associated proteins (MRP1, 2 and 5) that are overexpressed
in pharmacoresistant epilepsy. Neuropharmacology 2010, 58, 1019−
1032.
(20) Chen, Y.-H.; Wang, C.-C.; Xiao, X.; Wei, L.; Xu, G. Multidrug
resistance-associated protein 1 decreases the concentrations of
antiepileptic drugs in cortical extracellular fluid in amygdale kindling
rats. Acta Pharmacol. Sin. 2013, 34, 473−479.
(21) Sultana, R.; Butterfield, D. A. Oxidatively modified GST and
MRP1 in Alzheimer’s disease brain: Implications for accumulation of
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm401764a | J. Med. Chem. 2014, 57, 1023−10321031
reactive lipid peroxidation products. Neurochem. Res. 2004, 29, 2215−
2220.
(22) Krohn, M.; Lange, C.; Hofrichter, J.; Scheffler, K.; Stenzel, J.;
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